Days after it was announced that the cost of Mounjaro weight-loss jabs in the UK will treble in September, sales of Ozempic ...

President Trump’s planned pharmaceutical tariffs threaten to hit many of the most common and well-known drugs that Americans ...

What started as a medical solution to diabetes has exploded into a worldwide weight-loss trend, with demand skyrocketing as ...

US President Donald Trump is preparing to impose tariffs on two of the world’s most strategically important industries, semiconductors and pharmaceuticals, measures that Washington says are necessary ...

A NEW drug developed to combat diabetes and obesity melts fat at double the rate of other GLP-1 drugs, scientists say. The ...

Although Novo Nordisk has been struggling for over a year, the relative discount may attract bullish speculators to NVO stock ...

BRITAIN has gone fat jab crazy — with sales of Wegovy soaring by more than 2,000 per cent in the past month. Dieters are ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Dr Shazia Malik - a consultant obstetrician and gynaecologist for The Portland Hospital - discussed the pros and cons of ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...